Christie P.M. Verkleij

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Christie P.M. Verkleij, Marloes E.C. Broekmans, Mark van Duin et al. · Blood Advances · 2021 · 163 citations · Full text

Medicine, Immunology, Pharmacology +16

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno et al. · The Lancet Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab

Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto et al. · Clinical Cancer Research · 2020 · 87 citations · Full text

Medicine, Immunology, Pharmacology +17

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos et al. · Blood Advances · 2023 · 78 citations · Full text

Life Sciences, Hematology, Immunology +17

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans et al. · Clinical Cancer Research · 2024 · 58 citations · Full text

Life Sciences, Hematology, Immunology +16